1. Home
  2. GPRK vs LCTX Comparison

GPRK vs LCTX Comparison

Compare GPRK & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Geopark Ltd

GPRK

Geopark Ltd

HOLD

Current Price

$8.12

Market Cap

397.8M

Sector

Energy

ML Signal

HOLD

Logo Lineage Cell Therapeutics Inc.

LCTX

Lineage Cell Therapeutics Inc.

HOLD

Current Price

$1.63

Market Cap

407.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GPRK
LCTX
Founded
2002
1990
Country
Colombia
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
397.8M
407.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
GPRK
LCTX
Price
$8.12
$1.63
Analyst Decision
Hold
Strong Buy
Analyst Count
1
3
Target Price
$8.50
$4.67
AVG Volume (30 Days)
548.8K
991.0K
Earning Date
02-25-2026
03-09-2026
Dividend Yield
1.54%
N/A
EPS Growth
N/A
N/A
EPS
0.65
N/A
Revenue
$525,938,000.00
$10,816,000.00
Revenue This Year
N/A
$6.32
Revenue Next Year
N/A
$124.49
P/E Ratio
$11.89
N/A
Revenue Growth
N/A
24.05
52 Week Low
$5.66
$0.37
52 Week High
$10.13
$2.09

Technical Indicators

Market Signals
Indicator
GPRK
LCTX
Relative Strength Index (RSI) 63.97 44.60
Support Level $7.40 $1.60
Resistance Level $7.70 $1.71
Average True Range (ATR) 0.27 0.08
MACD 0.09 -0.01
Stochastic Oscillator 96.29 12.77

Price Performance

Historical Comparison
GPRK
LCTX

About GPRK Geopark Ltd

GeoPark Ltd is a Latin American oil and gas exploration and production company with assets in Colombia, Ecuador, Chile, Brazil, and Argentina. The company generates revenue from the sale of crude oil, condensate, and natural gas, net of value-added tax and discounts related to the sale and overriding royalties due to the ex-owners of oil and gas properties where the royalty arrangements represent a retained working interest in the property.

About LCTX Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

Share on Social Networks: